NanoViricides Narrows Q1 Loss Amid Cash Crunch, Eyes NV-387 Milestones

TL;DR

**NNVC is burning cash and needs more, but their NV-387 pipeline could be a game-changer if they can fund it through trials.**

AI Summary

NanoViricides, Inc. (NNVC) reported a net loss of $1,785,058 for the three months ended September 30, 2025, a significant improvement from the $3,126,811 net loss in the same period of 2024. This 42.9% reduction in net loss was primarily driven by a substantial decrease in operating expenses, which fell from $3,167,834 in Q1 2024 to $1,796,685 in Q1 2025. Research and development expenses decreased by 48.7% to $993,066, and general and administrative expenses dropped by 34.9% to $803,619. The company's cash and cash equivalents stood at $1,125,711 as of September 30, 2025, down from $1,558,564 at June 30, 2025. NNVC raised approximately $6 million in additional capital between October 1, 2025, and November 12, 2025, through ATM sales and a registered direct offering. Despite these efforts, management believes current cash, along with recent capital raises and a $3 million line of credit, will not be sufficient to fund operations for at least 12 months, raising substantial doubt about its ability to continue as a going concern. The company is focused on advancing its broad-spectrum antiviral drug NV-387 into Phase II clinical trials for MPox, Smallpox, and Measles, and exploring a basket-style Phase II trial for various respiratory viral infections.

Why It Matters

For investors, NNVC's reduced net loss is a positive sign, but the persistent 'going concern' warning and reliance on dilutive financing remain critical concerns. The company's strategic focus on NV-387 for MPox, Smallpox, and Measles, coupled with potential Orphan Drug Designations, could offer a faster regulatory pathway and government funding opportunities, which would be a significant de-risking event. However, the competitive landscape for antiviral therapeutics is intense, with larger pharmaceutical companies often having deeper pockets for R&D and commercialization. Employees face uncertainty given the company's financial instability, while customers and the broader market could benefit from successful development of broad-spectrum antiviral drugs, addressing critical unmet medical needs.

Risk Assessment

Risk Level: high — The company explicitly states 'substantial doubt exists about the Company's ability to continue as a going concern' due to an accumulated deficit of $150.6 million and projected insufficient cash to fund operations for 12 months. Despite recent capital raises of approximately $6 million, the company has not generated any revenues and anticipates continued losses, indicating a high financial risk.

Analyst Insight

Investors should exercise extreme caution and consider NNVC a highly speculative investment. Monitor closely for updates on NV-387 clinical trial progress and further financing activities, as successful trial outcomes or non-dilutive funding could significantly alter the risk profile, but the current financial runway is very short.

Financial Highlights

debt To Equity

0.16

revenue

$0

operating Margin

-100.0%

total Assets

$ 8,357,080

total Debt

$ 1,182,386

net Income

$ -1,785,058

eps

$ -0.10

gross Margin

N/A

cash Position

$ 1,125,711

revenue Growth

N/A

Key Numbers

• $1,785,058 — Net Loss (for the three months ended September 30, 2025, a 42.9% reduction from prior year)
• $1,125,711 — Cash and Cash Equivalents (as of September 30, 2025, down from $1,558,564 at June 30, 2025)
• $150,626,919 — Accumulated Deficit (as of September 30, 2025, indicating significant historical losses)
• $993,066 — Research and Development Expenses (for the three months ended September 30, 2025, a 48.7% decrease year-over-year)
• $803,619 — General and Administrative Expenses (for the three months ended September 30, 2025, a 34.9% decrease year-over-year)
• $6,000,000 — Additional Capital Raised (between October 1, 2025, and November 12, 2025)
• 17,556,079 — Common Shares Outstanding (as of September 30, 2025, up from 16,606,832 at June 30, 2025, indicating dilution)
• $0.10 — Net Loss Per Common Share (for the three months ended September 30, 2025, improved from $0.23 in prior year)

Key Players & Entities

• NANOVIRICIDES, INC. (company) — clinical stage nano-biopharmaceutical company
• NV-387 (product) — broad-spectrum antiviral drug candidate
• D. Boral Capital (company) — Sales Agent for At-The-Market (ATM) agreement
• US FDA (regulator) — regulatory authority for drug approvals
• India (country) — location for planned Phase Ia/Ib and Phase II clinical trials
• MPox (disease) — target indication for NV-387 Phase II clinical trial
• Smallpox (disease) — target indication for NV-387 Orphan Drug Designation
• Measles (disease) — target indication for NV-387 Orphan Drug Designation

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company's current cash of $1,125,711 as of September 30, 2025, combined with recent capital raises of approximately $6 million and a $3 million line of credit, is not expected to be sufficient to fund operations for at least 12 months. This raises substantial doubt about NanoViricides, Inc.'s ability to continue as a going concern.
• Significant Accumulated Deficit [medium — financial]: NanoViricides, Inc. has an accumulated deficit of $150,626,919 as of September 30, 2025. This indicates a history of substantial losses, which is a common characteristic of early-stage biotechnology companies but represents a significant financial hurdle.
• Dilution from Capital Raises [medium — financial]: The number of common shares outstanding increased from 16,606,832 at June 30, 2025, to 17,556,079 at September 30, 2025. This 5.7% increase, along with the recent capital raises, suggests potential dilution for existing shareholders.
• Dependence on Clinical Trial Success [high — operational]: The company's future success is heavily reliant on the advancement of its drug candidate NV-387 into and through Phase II clinical trials for MPox, Smallpox, and Measles, as well as other respiratory viral infections. Failure in these trials would significantly impact the company's prospects.
• Regulatory Approval Pathway [high — regulatory]: Navigating the complex and lengthy regulatory approval process for new antiviral drugs is a significant challenge. Delays or failures in obtaining regulatory approval from bodies like the FDA can severely impact market entry and commercialization.

Industry Context

NanoViricides, Inc. operates in the highly competitive and capital-intensive biotechnology sector, focusing on antiviral drug development. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Success hinges on clinical trial outcomes and the ability to secure substantial funding for research, development, and eventual commercialization.

Regulatory Implications

The company's primary regulatory challenge lies in successfully navigating the FDA approval process for its drug candidate NV-387. This involves rigorous clinical trials and adherence to strict Good Manufacturing Practices (GMP). Any delays or setbacks in the regulatory pathway could significantly impede market entry and revenue generation.

What Investors Should Do

1. Monitor cash burn and future capital raises.
2. Track progress of NV-387 clinical trials.
3. Evaluate the impact of reduced operating expenses.

Key Dates

• 2025-09-30: End of Q1 Fiscal Year 2026 — Reporting period for the condensed financial statements, showing a reduced net loss and cash position.
• 2025-10-01: Start of Capital Raising Period — Beginning of the period during which NNVC raised approximately $6 million through ATM sales and a registered direct offering.
• 2025-11-12: End of Capital Raising Period — Conclusion of the period for the reported capital raises, highlighting the company's ongoing need for funding.

Glossary

Accumulated Deficit

The cumulative net losses of a company since its inception, minus any cumulative net income. It represents the total loss that has not been offset by profits. (Indicates the company's historical unprofitability, with a significant deficit of $150,626,919 as of September 30, 2025.)

Going Concern

An assumption that a company will continue to operate for the foreseeable future, typically at least 12 months. If there is substantial doubt about this, it must be disclosed. (Management has expressed substantial doubt about NNVC's ability to continue as a going concern, highlighting financial instability.)

ATM Sales

At-The-Market offerings, where a company sells its shares on a stock exchange over a period of time at prevailing market prices. (A method used by NNVC to raise approximately $6 million in additional capital, contributing to its funding efforts.)

Registered Direct Offering

A type of public offering where a company sells newly issued securities directly to a small group of institutional investors, rather than through an underwriter. (Another method used by NNVC to raise capital, alongside ATM sales, indicating a need for immediate funding.)

Net Loss Per Common Share

The portion of a company's profit or loss allocated to each outstanding share of common stock. Calculated by dividing net income (or loss) by the weighted-average number of outstanding common shares. (Improved to -$0.10 for the three months ended September 30, 2025, from -$0.23 in the prior year, reflecting a reduced loss.)

Year-Over-Year Comparison

Compared to the prior year's comparable period, NanoViricides, Inc. has significantly reduced its net loss by 42.9%, from $3,126,811 to $1,785,058. This improvement is largely due to a substantial decrease in operating expenses, with R&D falling 48.7% and G&A dropping 34.9%. However, cash and cash equivalents have decreased from $1,558,564 to $1,125,711, and the company continues to face substantial doubt regarding its ability to continue as a going concern, despite recent capital raises.

Key Financial Figures

• $0.00001 — Preferred Common Stock: Stock: Par $0.00001 Par $0.00001 Number Number Addi

Filing Documents

• nnvc-20250930x10q.htm (10-Q) — 1151KB
• nnvc-20250930xex31d1.htm (EX-31.1) — 11KB
• nnvc-20250930xex31d2.htm (EX-31.2) — 11KB
• nnvc-20250930xex32d1.htm (EX-32.1) — 6KB
• nnvc-20250930xex32d2.htm (EX-32.2) — 6KB
• 0001104659-25-112608.txt ( ) — 4930KB
• nnvc-20250930.xsd (EX-101.SCH) — 41KB
• nnvc-20250930_cal.xml (EX-101.CAL) — 32KB
• nnvc-20250930_def.xml (EX-101.DEF) — 185KB
• nnvc-20250930_lab.xml (EX-101.LAB) — 311KB
• nnvc-20250930_pre.xml (EX-101.PRE) — 245KB
• nnvc-20250930x10q_htm.xml (XML) — 690KB

FINANCIAL INFORMATION

PART I FINANCIAL INFORMATION 3

Financial Statements

Item 1. Financial Statements 3 Condensed Balance Sheets at September 30, 2025 (Unaudited) and June 30, 2025 3 Condensed Statements of Operations for the Three Months Ended September 30, 2025 and 2024 (Unaudited) 4 Condensed Statements of Changes in Stockholders' Equity for the Three Months Ended September 30, 2025 and 2024 (Unaudited) 5 Condensed Statements of Cash Flows for the Three Months Ended September 30, 2025 and 2024 (Unaudited) 7 Notes to the Condensed Financial Statements (Unaudited) 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 20

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 48

Controls and Procedures

Item 4. Controls and Procedures 49

OTHER INFORMATION

PART II OTHER INFORMATION 50

Legal Proceedings

Item 1. Legal Proceedings 50

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 50

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 51

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 52

Other Information

Item 5. Other Information 52

Exhibits and Reports on Form 8-K

Item 6. Exhibits and Reports on Form 8-K 53

Signatures

Signatures 54 Certifications 2 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements NanoViricides, Inc. Condensed Balance Sheets September 30, June 30, 2025 2025 (Unaudited) ASSETS CURRENT ASSETS: Cash and cash equivalents $ 1,125,711 $ 1,558,564 Prepaid expenses 126,855 112,146 Total current assets 1,252,566 1,670,710 Property and equipment, net 6,787,456 6,833,891 Intangible assets, net 314,971 317,039 OTHER ASSETS Service agreements 2,087 2,445 Total assets $ 8,357,080 $ 8,824,085 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable $ 254,943 $ 459,094 Accounts payable – related party 901,143 821,456 Accrued expenses 26,300 25,969 Total current liabilities 1,182,386 1,306,519 COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' EQUITY: Series A convertible preferred stock, $ 0.00001 par value, 10,000,000 shares designated, 916,308 and 905,717 shares issued and outstanding, at September 30, 2025 and June 30, 2025, respectively 9 9 Common stock, $ 0.00001 par value; 150,000,000 shares authorized, 17,556,079 and 16,606,832 shares issued and outstanding, at September 30, 2025 and June 30, 2025, respectively 176 166 Additional paid-in capital 157,801,428 156,359,252 Accumulated deficit ( 150,626,919 ) ( 148,841,861 ) Total stockholders' equity 7,174,694 7,517,566 Total liabilities and stockholders' equity $ 8,357,080 $ 8,824,085 See accompanying notes to the condensed financial statements 3 Table of Contents NanoViricides, Inc. (Unaudited) For the Three Months Ended September 30, 2025 2024 OPERATING EXPENSES Research and development $ 993,066 $ 1,933,091 General and administrative 803,619 1,234,743 Total operating expenses 1,796,685 3,167,834 LOSS FROM OPERATIONS ( 1,796,685 ) ( 3,167,834 ) OTHER INCOME Interest income 11,627 41,023 Other income, net 11,627 41,023 NET LOSS $ ( 1,785,058 ) $ ( 3,126,811 ) Net loss per co

View Full Filing

View this 10-Q filing on SEC EDGAR